Market leadership Position MMI as the pioneer in microsurgery robotics with the Symani Surgical System, highlighting its unique capability to perform robotic microsurgery on tiny vessels and lymphatics to address complex cases that current methods cannot efficiently treat.

Strategic funding Leverage the strong investor backing and recent Series C funding to engage potential customers with evidence of financial stability and rapid growth, using funding momentum to accelerate adoption and expand global deployments.

Award validation Highlight Edison Award recognition in health and biotech to build credibility with hospitals and surgeons, using third‑party validation to open conversations about replacing or augmenting existing microsurgical capabilities.

Global expansion Capitalize on the international footprint indicated by MMI Srl operations and announcements of new microsurgery systems, targeting leading academic centers and high-volume tertiary care hospitals seeking advanced microsurgical options.

Clinical outcomes Emphasize the potential to improve patient quality of life and expand treatment options for difficult conditions, offering case studies and ROI data on reduced operative tremor, precision improvements, and faster recovery to drive adoption among surgeons and procurement teams.